Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025 1. Similar to the 2005-2006 ...

Thousands have been infected and two have been killed by the debilitating, mosquito-borne virus in the space of a few weeks ...

weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug Administration to prevent disease ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...

The agency has published a list of 24 high-risk infectious diseases as a reference tool for funders and researchers.

Analysts have recently evaluated Valneva and provided 12-month price targets. The average target is $17.5, accompanied by a ...

The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

Within the framework of its CEPI agreement, Valneva also announced an exclusive license agreement with the Serum Institute of India (SII)17 to enable supply of its chikungunya vaccine in Asia.

If granted, IXCHIQ ® will become the first vaccine against the ... M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing ...

This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an ...